Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Acta oncologica

• Publication date

  2016-10-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/0284186X.2016.1235797PMID 27762654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.

  2015cited by this paper
• Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer

  2015cited by this paper
• Impact of Total Lymph Node Count on Staging and Survival After Neoadjuvant Chemoradiation Therapy for Rectal Cancer

  2015cited by this paper
• High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.

  2015cited by this paper
• Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

  2015cited by this paper
• Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.

  2014cited by this paper
• Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

  2014cited by this paper
• Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis.

  2014cited by this paper
• Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.

  2014cited by this paper
• O-0017PREOPERATIVE CHEMORADIOTHERAPY AND POSTOPERATIVE CHEMOTHERAPY WITH CAPECITABINE AND OXALIPLATIN VS. CAPECITABINE ALONE IN LOCALLY ADVANCED RECTAL CANCER: DISEASE FREE SURVIVAL AT INTERIM ANALYSIS

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer.

  2013cited by this paper
• Need for objective and reproducible criteria in histopathological assessment of total mesorectal excision specimens: lessons from a national improvement project

  2013cited by this paper
• The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy

  2012cited by this paper
• A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial

  2012cited by this paper
• Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.

  2012cited by this paper
• Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.

  2011cited by this paper
• Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.

  2011cited by this paper
• Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

  2011cited by this paper
• Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

  2010cited by this paper
• Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?

  2008cited by this paper
• The TME Trial After a Median Follow-up of 6 Years: Increased Local Control But No Survival Benefit in Irradiated Patients With Resectable Rectal Carcinoma

  2007cited by this paper
• Chemotherapy with Preoperative Radiotherapy in Rectal Cancer

  2007cited by this paper
• Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival.

  2006cited by this paper
• Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example.

  2006cited by this paper
• Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

  2006cited by this paper
• Chemotherapy with preoperative radiotherapy in rectal cancer.

  2006cited by this paper
• Preoperative versus postoperative chemoradiotherapy for rectal cancer.

  2004cited by this paper
• Rate of Pathologic Complete Response With Increased Interval Between Preoperative Combined Modality Therapy and Rectal Cancer Resection

  2004cited by this paper
• Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial.

  1999cited by this paper
• Clinical Investigation : Gastrointestinal Cancer Optimal Timing for Assessment of Tumor Response to Neoadjuvant Chemoradiation in Patients With Rectal Cancer : Do All Patients Benefit From Waiting Longer Than 6 Weeks ?

  year unknowncited by this paper

• Controversies and Perspectives in the Current Management of Patients with Locally Advanced Rectal Cancer—A Systematic Review

  2025cites this paper
• INCORPORATING INDIVIDUAL EARLY RESPONSE IN THE DOSE-EFFECT RELATIONSHIP OF COMPLETE PATHOLOGICAL RESPONSE FOLLOWING NEO-ADJUVANT RADIO-CHEMOTHERAPY FOR RECTAL CANCER.

  2025cites this paper
• High-Dose-Rate Endorectal Brachytherapy Boost for Low-Lying Rectal Cancer: Predictors of Complete Clinical Response

  2025cites this paper
• Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer

  2024cites this paper
• Does complete pathological response increase perioperative morbidity risk in rectal cancer?

  2024cites this paper
• Is Nonoperative Management of Rectal Cancer Feasible?

  2023cites this paper
• Radiological Biomarkers in MRI directed Rectal Cancer Radiotherapy Volume Delineation

  2023cites this paper
• Nonoperative Management for Rectal Cancer.

  2022cites this paper
• Retrospective Evaluation of the Impact of Dose Escalation Using Pre-operative Simultaneous Integrated Boost Volumetric Modulated Arc Therapy on the Outcome of Locally Advanced Rectal Cancer Patients

  2022cites this paper
• Understanding the Benefit of Magnetic Resonance-guided Adaptive Radiotherapy in Rectal Cancer Patients: a Single-centre Study.

  2022cites this paper
• Image-Guided Brachytherapy for Rectal Cancer: Reviewing the Past Two Decades of Clinical Investigation

  2022cites this paper
• MORPHEUS Phase II–III Study: A Pre-Planned Interim Safety Analysis and Preliminary Results

  2022cites this paper
• Quantitative analysis of diffusion weighted imaging in rectal cancer during radiotherapy using a magnetic resonance imaging integrated linear accelerator

  2022cites this paper
• Identifying the long-term survival beneficiary of preoperative radiotherapy for rectal cancer in the TME era

  2022cites this paper
• Do the Locally Advanced Rectal Cancer Patients Enjoy Long-term Survival Benefit From the Radiation-based Neoadjuvant Treatments in the Total Mesorectal Excision Era: a Population-based Analysis

  2021cites this paper
• Neoadjuvant chemotherapy without radiation as a potential alternative treatment for locally advanced rectal cancer: A meta-analysis

  2021cites this paper
• Patterns of care, tolerability and safety of the first cohort of patients treated on a novel high-field MR-Linac within the MOMENTUM Study: Initial results from a prospective Multi-Institutional Registry.

  2021cites this paper
• When Should We Expect Curative Results of Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients?

  2021cites this paper
• Modeling precision genomic-based radiation dose response in rectal cancer.

  2020cites this paper
• Dose–time fractionation schedules of preoperative radiotherapy and timing to surgery for rectal cancer

  2020cites this paper
• Adding Boost to Standard Neoadjuvant Radiation for Rectal Cancer Improves Likelihood of Complete Response

  2020cites this paper
• Predicting pathological response after radio-chemotherapy for rectal cancer: impact of late oxaliplatin administration.

  2020cites this paper
• Unintended consequences of treating early rectal cancers for complete clinical response with chemoradiotherapy

  2020cites this paper
• Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac; clinical implementation and initial experience.

  2020cites this paper
• Evaluation of Preoperative Short Course Intensity Modulated Radiation Therapy in Treatment of Locally Advanced Rectal Carcinoma.

  2020cites this paper
• Magnetic Resonance Guided Radiotherapy for Rectal Cancer: Expanding Opportunities for Non-Operative Management

  2020influential citation
• Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review

  2020cites this paper
• Multidisciplinary Treatment of Rectal Cancer

  2020cites this paper
• A Phase I dose escalation trial using Intensity-Modulated Radiotherapy with simultaneous integrated boost in Pelvic Chemoradiotherapy for Metastatic Rectal Cancer

  2020cites this paper
• Watch and Wait in Rectal Cancer Patients with Clinical Complete Response to Neoadjuvant Therapy: The American Viewpoint

  2019cites this paper
• Image-Guided Adaptive Endorectal Brachytherapy in the Non-Operative Management of Patients with Rectal Cancer.

  2019cites this paper
• Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study.

  2019cites this paper
• MRI visibility of gold fiducial markers for image-guided radiotherapy of rectal cancer.

  2019cites this paper
• The Swedish Approach Towards Radiotherapy and Rectal Cancer: Making Sense of Where They Have Been and Where They Are Going

  2019cites this paper
• Feasibility of gold fiducial markers as a surrogate for GTV position in image-guided radiotherapy of rectal cancer.

  2019cites this paper
• How Long to Wait After Preoperative Radio(Chemo) Therapy to Perform Surgery

  2018cites this paper
• R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy

  2018cites this paper
• Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.

  2018cites this paper
• Prognostic markers of recurrence and survival in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery

  2018cites this paper
• What treatments should be skipped or intensified in localized rectal cancer?

  2018cites this paper
• High-Dose-Rate Brachytherapy in the Management of Operable Rectal Cancer: A Systematic Review.

  2017cites this paper
• On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery

  2017cites this paper
• Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

  2017cites this paper
• Watch-and-wait Approach for Clinical Complete Responders after Neoadjuvant Chemoradiotherapy for Rectal Cancer

  2017cites this paper
• Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era

  2017cites this paper
• Complete response nach Radiochemotherapie des Rektumkarzinoms – was tun?

  2017cites this paper
• A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer

  2017cites this paper
• Rethink radiotherapy – BIGART 2017

  2017cites this paper
• What is most relevant in preoperative rectal cancer chemoradiotherapy – the chemotherapy, the radiation dose or the timing to surgery?

  2016influential citation
• Multidisciplinary Treatment of Colorectal Cancer: Staging – Treatment – Pathology – Palliation

  2015cites this paper
• Feasibility of Gold Fiducial Markers as a Surrogate for Gross Tumor Volume Position in Image-Guided Radiation Therapy of Rectal Cancer

  year unknowncites this paper